Pantoprazole Zentiva (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazole Zentiva, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults.

GNH USA supplies Pantoprazole Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Zentiva is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive oesophagitis: accelerates mucosal healing of damage caused by stomach acid. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare neuroendocrine tumor. - Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually transient. - Nausea or vomiting: occasional gastrointestinal upset. - Abdominal pain: mild discomfort. - Flatulence: increased gas production. - Constipation: infrequent bowel changes.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: signs of hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash.

Before initiating therapy with Pantoprazole Zentiva, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Evaluate hepatic status: monitor liver enzymes in patients with liver disease. - Review long‑term use: limit duration to the shortest effective period to reduce fracture risk. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Concomitant medications: check for potential drug‑drug interactions, especially with antiplatelet agents. - Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of these interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Antiplatelet agents (e.g., clopidogrel): reduced antiplatelet activity may increase cardiovascular event risk. - HIV protease inhibitors (e.g., atazanavir): decreased absorption can lead to treatment failure.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect may require INR monitoring. - Methotrexate: reduced renal clearance can increase toxicity. - Digoxin: higher serum levels may occur, necessitating cardiac monitoring. - Oral antifungals (e.g., ketoconazole, itraconazole): decreased absorption may lower efficacy.